Literature DB >> 15833361

Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures.

Sergey G Kremlev1, Charles Palmer.   

Abstract

Inflammation contributes to perinatal brain injury and can be induced by hypoxia-ischemia (HI) or exposure to infection (fetal inflammatory response). The anti-inflammatory cytokine interleukin-10 (IL10) has been shown to have neuroprotective effects following HI. To determine whether IL10 can reduce the inflammatory response to lipopolysaccharide (LPS) in microglial cell cultures, primary microglial (MG) and/or HAPI cells (new MG-like cell line) were treated with LPS (50 ng/ml) in the presence or absence of IL10 (20 ng/ml) for 0.5, 1, 4, and 8 h. TNFalpha, MIP-1alpha, and RANTES were assayed by ELISA. Chemokine receptors, CCR5, CXCR3, and CX3CR1 (fractalkine receptor) were assayed by semiquantitative RT-PCR. We found that in MG cell cultures TNFalpha, MIP-1alpha, and RANTES release after 8-h exposure to LPS was significantly higher compared to non-exposed MG cells (P < 0.001). In HAPI cell cultures similar stimulation of mRNA levels was found for TNFalpha, MIP-1alpha, CXCR3, and CX3CR1. IL10 inhibited TNFalpha, MIP-1alpha, and RANTES release of LPS-stimulated MG cells as well as TNFalpha, MIP-1alpha, and CXCR3 mRNA expression by HAPI cells after exposure to LPS (P < 0.05). In contrast to those inhibitory effects, there was no change in fractalkine, and a modest increase in CX3CR1 mRNA levels was found in the presence of IL10. We conclude that the inflammatory response induced in microglial cells by LPS can be markedly reduced by IL10. The increase in fractalkine receptor (CX3CR1) is also potentially protective. Our results suggest that treatment of damaging neuroinflammatory insults such hypoxia-ischemia, with IL10 may be protective for the immature brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833361     DOI: 10.1016/j.jneuroim.2005.01.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  44 in total

1.  SCH58261 the selective adenosine A(2A) receptor blocker modulates ischemia reperfusion injury following bilateral carotid occlusion: role of inflammatory mediators.

Authors:  R A Mohamed; A M Agha; N N Nassar
Journal:  Neurochem Res       Date:  2011-11-10       Impact factor: 3.996

Review 2.  The role of the microglia in acute CNS injury.

Authors:  Masahito Kawabori; Midori A Yenari
Journal:  Metab Brain Dis       Date:  2014-03-29       Impact factor: 3.584

Review 3.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

Review 4.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Trends Immunol       Date:  2008-07-01       Impact factor: 16.687

5.  T cells from Leishmania major-susceptible BALB/c mice have a defect in efficiently up-regulating CXCR3 upon activation.

Authors:  Joseph Barbi; Frank Brombacher; Abhay R Satoskar
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 6.  Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury.

Authors:  Jenna M Ziebell; Maria Cristina Morganti-Kossmann
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

Review 7.  Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift.

Authors:  Yasir N Jassam; Saef Izzy; Michael Whalen; Dorian B McGavern; Joseph El Khoury
Journal:  Neuron       Date:  2017-09-13       Impact factor: 17.173

8.  TGFβ produced by IL-10 redirected astrocytes attenuates microglial activation.

Authors:  Diana M Norden; Ashley M Fenn; Allison Dugan; Jonathan P Godbout
Journal:  Glia       Date:  2014-02-25       Impact factor: 7.452

Review 9.  Traumatic brain injury, neuroinflammation, and post-traumatic headaches.

Authors:  Cynthia L Mayer; Bertrand R Huber; Elaine Peskind
Journal:  Headache       Date:  2013-07-08       Impact factor: 5.887

10.  The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease.

Authors:  Josh M Morganti; Kevin R Nash; Bethany A Grimmig; Sonali Ranjit; Brent Small; Paula C Bickford; Carmelina Gemma
Journal:  J Neurosci       Date:  2012-10-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.